Schellekens H - Search Results

1

Immunogenicity of bone morphogenetic proteins.

Hwang CJ, Vaccaro AR, Lawrence JP, Hong J, Schellekens H, Alaoui-Ismaili MH, Falb D. Hwang CJ, et al. Among authors: schellekens h. J Neurosurg Spine. 2009 May;10(5):443-51. doi: 10.3171/2009.1.SPINE08473. J Neurosurg Spine. 2009. PMID: 19442006 Review.

2

The immunogenicity of therapeutic proteins.

Schellekens H. Schellekens H. Discov Med. 2010 Jun;9(49):560-4. Discov Med. 2010. PMID: 20587346 Free article.

3

Immunogenicity of therapeutic proteins: clinical implications and future prospects.

Schellekens H. Schellekens H. Clin Ther. 2002 Nov;24(11):1720-40; discussion 1719. doi: 10.1016/s0149-2918(02)80075-3. Clin Ther. 2002. PMID: 12501870 Review.

4

Structure-immunogenicity relationships of therapeutic proteins.

Hermeling S, Crommelin DJ, Schellekens H, Jiskoot W. Hermeling S, et al. Among authors: schellekens h. Pharm Res. 2004 Jun;21(6):897-903. doi: 10.1023/b:pham.0000029275.41323.a6. Pharm Res. 2004. PMID: 15212151 Review.

5

Natural antibodies against bone morphogenic proteins and interferons in healthy donors and in patients with infections linked to type-1 cytokine responses.

Sauerborn M, van de Vosse E, Delawi D, van Dissel JT, Brinks V, Schellekens H. Sauerborn M, et al. Among authors: schellekens h. J Interferon Cytokine Res. 2011 Sep;31(9):661-9. doi: 10.1089/jir.2010.0075. Epub 2011 May 25. J Interferon Cytokine Res. 2011. PMID: 21612442

6

Immunogenicity of recombinant human proteins: causes and consequences.

Schellekens H, Casadevall N. Schellekens H, et al. J Neurol. 2004 Jun;251 Suppl 2:II4-9. doi: 10.1007/s00415-004-1202-9. J Neurol. 2004. PMID: 15264106 Review.

7

Immunogenicity of rDNA-derived pharmaceuticals.

Ryff JC, Schellekens H. Ryff JC, et al. Among authors: schellekens h. Trends Pharmacol Sci. 2002 Jun;23(6):254-6. doi: 10.1016/s0165-6147(02)02024-2. Trends Pharmacol Sci. 2002. PMID: 12084625 Review.

8

On the role of aggregates in the immunogenicity of recombinant human interferon beta in patients with multiple sclerosis.

van Beers MM, Jiskoot W, Schellekens H. van Beers MM, et al. Among authors: schellekens h. J Interferon Cytokine Res. 2010 Oct;30(10):767-75. doi: 10.1089/jir.2010.0086. J Interferon Cytokine Res. 2010. PMID: 20874254 Review.

9

Development of a transgenic mouse model to study the immunogenicity of recombinant human insulin.

Torosantucci R, Brinks V, Kijanka G, Halim LA, Sauerborn M, Schellekens H, Jiskoot W. Torosantucci R, et al. Among authors: schellekens h. J Pharm Sci. 2014 May;103(5):1367-74. doi: 10.1002/jps.23935. Epub 2014 Mar 11. J Pharm Sci. 2014. PMID: 24619587

10

The immunogenicity of biopharmaceuticals. Lessons learned and consequences for protein drug development.

Patten PA, Schellekens H. Patten PA, et al. Among authors: schellekens h. Dev Biol (Basel). 2003;112:81-97. Dev Biol (Basel). 2003. PMID: 12762507

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

321 results

Search Page